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Background: The functional state of glial cells, like astrocytes and microglia, critically modulates the course of
neuroinflammatory and neurodegenerative diseases and can have both detrimental and beneficial effects. Glial cell
function is tightly controlled by cellular interactions in which cytokines are important messengers. Recent studies
provide evidence that in particular chemokines are important modulators of glial cell function. During the course of
CNS diseases like multiple sclerosis or Alzheimer’s disease, and in the corresponding animal models, the
chemokines CXCL9 and CXCL10 are abundantly expressed at sites of glial activation, arguing for an important role
of these chemokines and their corresponding receptor CXCR3 in glial activation. To clarify the role of this
chemokine system in glial cell activation, we characterized the impact of CXCR3 on glial activation in a model of
toxic demyelination in which glial activation without a prominent influx of hematogenous cells is prototypical.
Methods: We investigated the impact of CXCR3 on cuprizone-induced demyelination, comparing CXCR3-deficient
mice with wild type controls. The clinical course during cuprizone feeding was documented for five weeks and for
the subsequent four days withdrawal of the cuprizone diet (5.5 weeks). Glial activation was characterized using
histological, histomorphometric and phenotypic analysis. Molecular analysis for (de)myelination and neuroinflammation
was applied to characterize the effect of cuprizone on CXCR3-deficient mice and control animals.
Results: CXCR3-deficient mice displayed a milder clinical course during cuprizone feeding and a more rapid body
weight recovery after offset of diet. In the CNS, CXCR3 deficiency significantly attenuated the accumulation and
activation of microglia and astrocytes. Moreover, a deficiency of CXCR3 reduced the expression of the microglial
activation markers CD45 and CD11b. Compared to controls, we observed a vast reduction of RNA levels for
proinflammatory cytokines and chemokines like Ccl2, Cxcl10, Tnf and Il6 within the CNS of cuprizone-treated mice.
Lastly, CXCR3 deficiency had no major effects on the course of demyelination during cuprizone feeding.
Conclusions: The CXCR3 chemokine system is critically involved in the intrinsic glial activation during
cuprizone-induced demyelination, which significantly modulates the distribution of glial cells and the local
cytokine milieu.
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Glial cells are essential for neuronal function and homeo-
stasis of the CNS [1-6]. In addition, glial cells are key par-
ticipators during pathological changes within the diseased
brain [7-10]. Both microglia and astrocytes can be rapidly
activated through mechanisms like pattern recognition
receptors detecting infectious and endogenous danger
signals [7,11-16]. In response, activated microglia and
astrocytes produce inflammatory mediators like cytokines
and chemokines, which critically modulate the course of
CNS diseases. Therefore, understanding the mechanisms
of glial activation is crucial to understanding the patho-
physiology of the CNS.
Recent studies suggest that the chemokine receptor
CXCR3 and the corresponding chemokine ligands CXCL9,
CXCL10 and CXCL11 are expressed during CNS diseases
and modulate glial functions like migration of microglia
or cytokine synthesis [17-26].
CXCR3 ligands in CNS diseases are produced by infil-
trating lympho- and monocytes but also by resident glial
cells on stimuli such as TLR ligands or pro-inflammatory
cytokines like IFN-gamma and TNF alpha [27-30]. The
corresponding chemokine receptor CXCR3 can be dif-
ferentially activated by the chemokine ligands CXCL9,
CXCL10 and CXCL11 [31-35]. CXCR3 mediates distinct
functions like integrin activation, cytoskeletal changes,
suppression of angiogenesis or chemotactic migration
[31,36-39]. Activated T cells and NK cells are well estab-
lished to express CXCR3 at high levels [40]. Moreover,
recent data argue for the functional existence of CXCR3
on microglia [23,41,42] and astrocytes [41,43]. CXCR3 sig-
naling has been mostly investigated during infectious, bac-
terial and autoimmune diseases of the CNS [18,24,44-52]
where immune cells infiltrate the CNS. However, the
impact of CXCR3 on glial function without a significant
influx of immune cells is not well characterized and
only addressed by a few studies [23,53].
Cuprizone intoxication in C57BL/6 mice leads to pri-
mary oligodendrocyte apoptosis accompanied by an over-
whelming activation of microglia and astrocytes in the
absence of lymphocyte influx from the blood [54-56].
Using the cuprizone model we wanted to determine the
impact of the CXCR3 chemokine system on endogenous
glial activation.
Indeed, our data demonstrate that CXCR3 critically
modulates the activation of glial cells by molecular and
morphological criteria during cuprizone-induced toxic
demyelination.
Methods
Animals and administration of cuprizone
Toxic demyelination was induced in 8-week-old wild
type C57BL/6 (WT, Charles River) and CXCR3-deficient
mice (CXCR3-/-; B6.129P2-Cxcr3tm1Dgen/J, JacksonLaboratory) fed with 0.2% (w/w) cuprizone (bis-cyclo-
hexanone oxaldihydrazone, Sigma-Aldrich, München,
Germany). Cuprizone was mixed into a powdered ground
standard rodent chow. Before cuprizone administration,
all mice of the study were adapted to powdered normal
chow for one week. Cuprizone diet was then maintained
for five weeks following four additional days on normal
chow, representing the stage of CNS-remyelination. As a
marker for the clinical outcome of cuprizone administra-
tion, the body weight of all mice was monitored twice a
week. A total of 4 to 5 WT and CXCR3-/- mice were an-
alyzed at each of the four time points of the experiment
(0, 3, 5, and 5 weeks + 4 additional days normal chow/
5.5 weeks). Animals were deeply anesthetized and trans-
cardially perfused with ice cold phosphate buffered sa-
line (PBS). Brains were removed immediately and cut
along the sagittal midline. Brain hemispheres were fixed
in 4% paraformaldehyde for 12 hours following paraffin-
embedding. The remaining hemisphere was further proc-
essed for flow cytometry and quantitative PCR analysis.
Routine histology and immunohistochemistry
A total of 8-μm thick paraffin-embedded sections were
rehydrated in graded ethanol series after deparaffination
in xylene and stained with hematoxylin and eosin (H&E)
or Luxol fast blue (LFB) for routine histological analysis
and myelin evaluation. For immunohistochemistry, sec-
tions were blocked with PBS containing 5% bovine serum
albumin (BSA fraction V, PAA) for 30 min. For the detec-
tion of myelin proteins, antibodies specific for the proteo-
lipid protein (PLP, Serotec; 1:200) and myelin basic
protein (MBP, Dako; 1:200) were incubated for one hour
at room temperature. Microglia cells were labeled using
biotinylated tomato lectin (Sigma-Aldrich; 1:50). After
washing in PBS, primary antibody treated sections were
incubated with the appropriate biotinylated secondary
antibody (Axxora; 1:200) before horseradish peroxidase-
coupled streptavidin was applied (Axxora; 1:200). The
signal was visualized by NovaRED color reagent (Vector
Laboratories), according to the manufacturer’s instruc-
tions. To further analyze activated microglia, immuno-
fluorescence stainings for ionized calcium binding adaptor
molecule 1 (Iba1, Wako; 1:500) and macrosialin (CD68,
Serotec; 1:500) combined with MBP antibody (Dako;
1:200) were applied. Sections were boiled with citric buffer
(pH 6.0) for 10 min and washed with PBS containing 0.1%
Triton-X 100 before standard blocking and antibody incu-
bation procedures. After washing in PBS, Alexa-555 and
Alexa-488 fluorescence-conjugated secondary antibodies
(Invitrogen; 1:200) were used to visualize the primary anti-
body. Sections were counterstained with DAPI (Sigma-
Aldrich) and mounted with fluorescent mounting medium
(Dako). Conventional and immunofluorescence-stained
sections were examined using the Eclipse E800 bright
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images and monochrome fluorescent images were ac-
quired using a SPOT FLEX 64 Mp Shifting Pixel CCD-
camera (model #15.2, Diagnostic Instruments Inc.,
Visitron Systems GmbH) and SPOT Basic Imaging
software (Visitron Systems GmbH).
Quantification of lectin+ microglia and evaluation of
the CD68+ and GFAP+ particle perimeter was per-
formed using ImageJ threshold/analyze particle features.
For high magnification images (CD68/Iba1 and GFAP/
lectin immunofluorescence) sections were analyzed using
a BX61 microscope equipped with a confocal disk scan-
ning unit (Olympus).
Flow cytometry analysis
The remaining half brains from WT and CXCR3-/- mice
were placed into ice-cold Hank’s BSS buffer solution
(PAA) and cut into small pieces. Samples were carefully
disrupted and homogenized using a Potter-Elvehjem Tis-
sue Grinder (10 ml; Wheaton), a needle (0.6 × 25) and a
syringe (5 ml) before passing through a 70-μm cell strainer
(BD Biosciences). After centrifugation, homogenates were
dissolved in 75% Percoll (GE-healthcare). Subsequently,
the homogenate was layered over with 25% Percoll and
PBS. After centrifugation at 800xg for 25 minutes/4°C
microglia were collected from the 25%/75% interface.
For surface marker staining, the collected cells were
washed in PBS, and blocked with CD16/CD32 (Fc block;
eBioscience) antibody. Isolated cells were incubated
with fluorochrome-conjugated antibodies (eBioscience)
to detect CD3e (PerCP-Cy5.5), CD11b (APC), CD11c
(PE-Cy7), CD45 (FITC), CD45 (eFluor 450), Ly6G
(PerCP-Cy5.5), B220 (APC-eFluor 780) and NK1.1 (PE-
Cy7). After washing, bound antibody was detected using
a BD FACSCanto II (BD Biosciences) and data were
analyzed using the flow cytometry software, FlowJo
(TreeStar). Microglia were gated using forward and
side scatter characteristics and identified by labelling
with CD11b and CD45 according to their typical expres-
sion profile. CD11b+/CD45dim microglia populations were
further analyzed for the mean fluorescence intensity of
CD11b and CD45. The percentage of CD11b+/CD45high
cells was expressed in comparison to CD11b+CD45dim+high
cells in the corresponding sample.
Cytokine and chemokine mRNA determination by
quantitative real-time polymerase chain reaction
Total RNA was isolated and purified from aliquots of ho-
mogenized brain samples using Trizol reagent (Sigma-
Aldrich). Homogenates with Trizol were roughly shaken
and disrupted using the Precellys homogenizer system
(Bertin technologies). RNA quantity was determined
using a NanoDrop 1000 (Peqlab). Up to 3 μg of total
RNA was reverse-transcribed into cDNA by usingSuperScript III Reverse Transcriptase (Invitrogen). Real-
time quantitative PCR assays were performed on a StepO-
nePlus Real-Time PCR System (Applied Biosystems) using
TaqMan™ Gene Expression Assays (Applied Biosystems)
for Gapdh, Plp1, Mbp, Cnp, Cxcl9, Cxcl10, Tnf, Il6, Ifng,
Ccl2, Ccl3, Ccl5. Samples were analyzed simultaneously
for Gapdh mRNA as the internal control. Each sample
was assayed in duplicate, normalized to the internal con-
trol and data was presented as copies of mRNA/Gapdh
(means ± SEM).
Statistical analysis
For all statistical analysis, differences between groups were
tested using GraphPad Prism 5 (GraphPad Software Inc).
One-way-ANOVA followed by Tukey’s post hoc test was
applied to evaluate differences between studied groups.
Statistical significance has been considered with a P value
≤0.05. All data are given as arithmetic means ± SEM.
Results
CXCR3-deficiency reduces clinical symptoms and weight
loss during cuprizone feeding
As previously shown, cuprizone feeding triggers growth
retardation and a decline of body weight in mice [57,58].
We documented the body weight development and
phenotypic signs for sickness in CXCR3-/- and WT mice
during the course of cuprizone feeding.
We found a scruffy coat combined with a hunched pos-
ture and ocular/nasal discharge as clinical symptoms for
cuprizone intoxication during the first three weeks of the
cuprizone-diet in most of the WT mice. These findings
were less overt in CXCR3-/- mice. We also observed an
overall higher locomotor activity of CXCR3-/- mice
compared to WT controls.
A rapid drop of body weight was detectable after the first
week of cuprizone feeding, when the body mass of WT
mice was reduced to 80.4 ± 0.9%, whereas in CXCR3-/-
mice dropped to 90.8 ± 1.9% (Figure 1; ***P <0.001) of
the initial weight (initial weight: WT 0 weeks: 19.4 ±
0.6 g, n = 20; CXCR3-/- 0 weeks: 18.8 ± 0.5 g, n = 20).
During the subsequent two weeks of cuprizone feeding,
the body weight remained at a significantly lower level
in WT compared to CXCR3-/- mice (Figure 1; WT,
2 weeks: 82.4 ± 1.0% versus CXCR3-/-, 2 weeks: 88.7 ±
1.4%, **P <0.01, n = 20; WT, 3 weeks: 80.1 ± 1.1% versus
CXCR3-/-, 3 weeks: 89.2 ± 1.7%, ***P <0.001, n = 20).
Between week three and four, WT mice increased their
weight by +5.5% to 85.6 ± 1.3% (n = 14), whereas
CXCR3-/- mice remained at 88.0 ± 2.8% (n = 14) of their
initial weight. From week four to five of cuprizone ad-
ministration no significant differences in the mean body
masses were detectable between both genotypes. With-
drawal of cuprizone after five weeks resulted in rapid
body weight recovery in WT and CXCR3-/- mice. The
Figure 1 Cuprizone administration induces a less overt body
weight decline in CXCR3-/- compared with wild type (WT) mice.
From 8 weeks of age, WT and CXCR3-/- mice were fed with 0.2%
cuprizone for five weeks (dotted grid lines) with a subsequent four
days of recovery to normal chow (5.5 weeks). The body weights
were monitored twice a week and plotted in comparison with
values of control animals fed with powdered normal chow (gray
symbols). During the initial three weeks of cuprizone feeding,
CXCR3-/- animals showed a significantly less pronounced body weight
decline than WT mice (n = 20 per group; **P <0.01, ***P <0.001).
Moreover, body weight recovery after offset of cuprizone feeding
was found to be significantly improved in CXCR3-deficient mice
after 5.5 weeks (n = 7 per group; ***P <0.001). Data represent
mean ± SEM.
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significantly higher in mice deficient for CXCR3 com-
pared to WT animals (Figure 1; WT 5.5 weeks: 105.9 ±
2.2%; CXCR3-/- 5.5 weeks: 117.7 ± 1.9%; *P <0.05).
CXCR3 is critical for the spatial distribution and activation
of microglia
As previously indicated, CXCR3 potentially influences the
functional properties of microglia during pathological
states of the CNS [23,53]. Here, we characterized the
impact of CXCR3 deficiency on microglia activation and
accumulation during cuprizone treatment. First, we de-
tected activated microglia in different brain regions:
corpus callosum (Cc), cerebellum (Cb) and thalamus
(Th) using tomato lectin staining, which was quantified
as a degree for microglial accumulation and activation.
Compared to WT, an attenuated amount of lectin+ sig-
nal was detected in the cerebellum of CXCR3-/- animals
(Figure 2B, Cb; WT, 3 weeks: 7.0 ± 0.8% versus CXCR3-/-,
3 weeks: 4.6 ± 0.7%, *P <0.05, lectin+ area fraction; WT,
5 weeks: 18.1 ± 1.4% versus CXCR3-/-, 5 weeks: 12.0 ±
1.9%). Moreover, strikingly diminished lectin staining
was found in the thalamus (Th), the midbrain and the
hypothalamus of CXCR3-/- mice (Figure 2B, Th; WT,
3 weeks: 1.9 ± 0.2% versus CXCR3-/- 3 weeks: 0.7 ± 0.1%,
***P <0.001; WT, 5 weeks: 4.5 ± 0.6% versus CXCR3-/-
5 weeks: 1.7 ± 0.5%, **P <0.01, lectin+ area fraction).
Together with attenuated microglia accumulation,
microglia showed a differential spatial distribution in the
cerebellum of CXCR3-/- animals. Consistently, we found
a rim-like formation of microglia in the deep cerebellarwhite matter (Figure 2D, Cb; 5 weeks CXCR3-/-) in
CXCR3 deficient brains. In contrast, WT mice displayed
a dense and even distribution of microglia in this area. In
difference to CXCR3-/- animals, we also found widespread
lectin+ cells in the medulla in WT mice (Figure 2D, Cb;
WT 5 weeks).
However, at the stage of acute demyelination after
three and five weeks, we observed comparable numbers
of lectin+ microglia in the corpus callosum of WT and
CXCR3-/- mice (Figure 2B, D; Cc).
Interestingly, microglia, localized in the white matter com-
ponents exhibit larger and round-shaped CD68+ compart-
ment in WT than in CXCR3-/- animals (Figure 2C, D; Cc).
Quantification of CD68-positive particles, as a marker for
microglial lysosomes, outlines a larger mean perimeter in
WT compared to CXCR3-/- mice in the corpus callosum
(Figure 2C, Cc; WT 5 weeks: 34.2 ± 0.7 μm (n = 1890)
versus CXCR3-/- 5 weeks 31.58 ± 0.67 μm, n = 2286,
**P <0.01), thalamus (Figure 2C, Th; WT 5 weeks: 22.0 ±
0.7 μm, n = 1442 versus CXCR3-/- 5 weeks: 18.5 ± 0.4 μm,
n = 2200, ***P <0.001) and cerebellum (Figure 2C, Cb; WT
5 weeks: 18.6 ± 0.3 μm, n = 4265 versus CXCR3-/- 5 weeks:
15.2 ± 0.3 μm, n = 2444, ***P <0.001) of CXCR3-/- mice.
To further define the alleviated microglia activation in
CXCR3-/- mice we co-localized Iba1 and CD68 to dif-
ferentiate activation by morphology and expression of a
lysosomal antigen. In cuprizone-treated WT animals,
tight clusters of activated Iba1+ microglia cells were vis-
ible. Microglia in these clusters displayed large CD68+
lysosomes, while in CXCR3-/- mice microglia distribu-
tion was loose and intracellular CD68+ lysosomes were
smaller in size and less prominent (Figure 3A).
Taken together, during cuprizone treatment, diminished
numbers and reduced activation of microglia were ob-
served in CXCR3deficient mice compared to WT.
Flow cytometry further confirms reduced microglial
activation in cuprizone-treated CXCR3-deficient mice
compared to wild type controls
The histological characterization of microglia in cuprizone-
treated mice outlined a differential spatial distribution,
accumulation and attenuated activation in CXCR3-/-
mice compared to control animals (Figure 2B-D and
Figure 3A). To further detect and substantiate differences
in the microglial phenotype during cuprizone administra-
tion, we applied flow cytometry of brain homogenates and
determined the CD11b and CD45 levels of microglia
populations.
As previously shown, CD45 levels can be helpful to
discriminate infiltrating macrophages/ microglia (CD11b+
/CD45high) or parenchymal microglia (CD11b+/CD45dim)
[56,59]. We assessed the percentage of CD11b+ cells ex-
pressing diminished (dim) or high levels of CD45 (high).
Initially, CD11b+/CD45dim microglia comprised 99.4% of
Figure 2 Diminished microglia cell numbers and extent of CD68+ content in CXCR3-/- cuprizone brains. A. Sagittal brain sections of wild
type (WT) and CXCR3-/- were analyzed for the localization of activated microglia at regions of the corpus callosum (Cc), thalamus (Th) and
cerebellum (Cb). B. Analysis of serial sagittal brain sections stained for tomato lectin documents a significant reduction of activated microglia in
cuprizone-fed CXCR3-/- mice compared to WT animals (n = 10 to 14 at equal sections, time point and genotype, *P <0.05, **P <0.005, ***P <0.001).
D. These observations were made within regions of the thalamus (Th) and cerebellum (Cb), but were not found in the white matter of the
frontal corpus callosum (Cc) of CXCR3-/- brains. Besides the reduced lectin+ area fraction in the cerebellum of CXCR3-/- mice, we also found a
differential spatial distribution of microglia surrounding the cerebellar nuclei together with a consistent cluster at the vestibular nuclei of the
medulla after 5 weeks (D, WT Cb versus CXCR3-/- Cb). {AU Query: Please define ‘D’ from the previous sentence so readers know what this
abbreviation represents.} Because most overt differences of microglia accumulation between CXCR3-/- and WT were visible after 5 weeks of
cuprizone diet, we further investigated microglia using double fluorescence immunolabeling for CD68 (red) and MBP (green) (Myelin basic protein).
C. At the designated insets (D) we analyzed the CD68+ content in both genotypes and found significantly reduced particle perimeters in all studied
central nervous system (CNS) regions in CXCR3-/- compared to WT brains (n ≥1,900 CD68+ particles per genotype, **P <0.01, ***P <0.001). Data
represent mean ± SEM.
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Figure 3). Throughout the experiment, these microglia
were visible as a distinct cell population (Figure 4B, left
encircled population in both genotypes). An overall low,
but significantly higher percentage of CD11b+/CD45high
cells were found in both WT and CXCR3-/- animals upon
cuprizone intoxication, peaking after 3 weeks of the study
(Figure 4 B; WT 0 weeks: 0.62 ± 0.16% versus WT 3 weeks:
5.29 ± 1.47%, *P <0.05; CXCR3-/- 0 weeks: 0.55 ± 0.06%
versus CXCR3-/- 3 weeks: 3.40 ± 0.48%, **P <0.01). Al-
though, the populations of CD11b+/CD45high microglia/
macrophages were slightly increased after 3 and 5 weeks
in WT animals, this difference did not reach a signifi-
cant t level when compared to CXCR3-/- mice.
We further analyzed the CD11b+/CD45dim microglia
population and found strongly reduced surface expres-
sion of CD45 on CXCR3-/- compared to WT micro-
glia after three and five weeks of cuprizone treatment
(Figure 3B-D). After three weeks of cuprizone ingestion,the reduction of CD45 and CD11b molecules on CXCR3-/-
microglia was most intense compared to WT mice
(Figure 3C; CD45, WT: 522.8 ± 6.5 versus CXCR3-/-:
382.3 ± 12.7, ***P <0.001; CD11b WT: 8912 ± 35.9 versus
CXCR3-/-: 7845 ± 202.0, MFI). After five weeks, the ex-
pression of microglial CD45 in CXCR3-/- mice was still
significantly lower than in WT mice (Figure 3C; CD45,
WT 3 weeks: 562.8 ± 7.4 versus CXCR3-/- 3 weeks:
503.6 ± 10.5, **P <0.005, MFI) whereas the CD11b ex-
pression reached the corresponding WT level.
The detection of other CD45+ leukocytes like neutro-
phils (Ly6-G), T cells (CD3e) and Nk cells (Nk 1.1) did not
lead to evaluable data. We found very low quantities of
other CD45-positive cells than the CD11b+/ CD45+ popu-
lation. The percentage of CD11b-negative CD45+ events
continuously lay below 1.3% in WT and CXCR3-/- ani-
mals (data not shown).
In summary, CD11b+/CD45dim CXCR3-/- microglia
displayed strongly diminished total level of the activation
Figure 3 CXCR3-deficient microglia display diminished levels for CD45 and CD11b during cuprizone diet. A. Ex vivo-prepared microglia of
both genotypes were phenotyped using flow cytometry. B. Brain homogenates from wild type (WT) and CXCR3-/- mice after 3, 5, and 5.5 weeks
of the cuprizone diet (n = 4 to 5 animals per group) were prepared and microglia subsequently analyzed for CD45 and CD11b expression. Using
CD11b/CD45 gating, the majority of microglia were found in a distinct isolated CD11b+/CD45dim population in WT and CXCR3-/- animals (left
encircled population). A small population of CD11b+/CD45high cells was slightly increased in WT compared to CXCR3-/- mice after 3 weeks (right
encircled population, percentage of CD11b+/CD45high cells is given below, mean ± SEM). C. Flow cytometry histogram overlays show representative
CD45/CD11b expression from freshly isolated microglia (CD11b+/CD45dim+high in WT (black line) and CXCR3-/- (red line) cuprizone-fed mice
after 3 weeks. The dashed histogram represents the isotype control. Histograms were gated on microglial population according to forward/side
scatter profile. CXCR3-/- animals displayed reduced surface expression levels for CD45 and CD11b compared with WT levels. D. Statistical
analysis of the CD45 and CD11b level within the CD11b+/CD45dim microglia population of WT (black dots) and CXCR3-/- (red dots) mice over
the course of the cuprizone experiment (mean fluorescence intensity, MFI). Fundamentally reduced MFI of CD45 (3 and 5 weeks) and CD11b
(3 weeks) were documented in CXCR3-/- compared to WT microglia (**P <0.005, ***P <0.001).
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tion when compared to WT controls. However, we could
not detect significant differences in the composition of
CD11b+/CD45dim and CD11b+/CD45high microglia/
macrophages between WT and CXCR3-deficient mice
throughout the cuprizone study.
Astrocyte activation by morphological criteria is reduced
in cuprizone-treated CXCR3-/- mice compared to wild
type controls
Subsequently, we prepared immunofluorescence stainings
for glial fibrillary acidic protein (GFAP) specific anti-
body combined with lectin to localize reactive astroglio-
sis within regions of microglia activation. Hypertrophic
astrocytic cell bodies were found in close proximity tothe corpus callosum (Cc) and within the thalamus (Th)
of WT, but were less pronounced in CXCR3-/- mice.
We quantified the extent of astrocytic activation in
terms of GFAP-positive cell body perimeters and found
reduced values in CXCR3-/- animals within the Cc and
Th regions investigated (Figure 5A; WT Cc: 49.9 ± 1.3 μm,
n = 1672 versus CXCR3-/-Cc: 45.4 ± 1.3 μm, n = 1303;
*P <0.05). This effect was most prominent in the thal-
amic region and in brain areas with high microglia ac-
cumulation in WT and CXCR3-/- mice (Figure 5A; WT
Th: 67.5 ± 3.2 μm, n = 1220 versus CXCR3-/- Th: 51.4 ±
2.3 μm, n = 930; ***P <0.001). Substantial overlapping of
neighboring astrocyte processes with confluent cellular
signals were detected in WT but not in CXCR3-/- ani-
mals (Figure 5B, Th; insets of original magnification). In
Figure 4 Cuprizone intoxication induces a robust demyelination of different brain regions in wild type (WT) and CXCR3-/-mice. A.
Sagittal brain sections of WT and CXCR3-/- were analyzed for the degree of (de-)myelination at regions of the corpus callosum (Cc), thalamus (Th)
and cerebellum (Cb) using immunofluorescence detection for myelin basic protein (MBP) and Luxol fast blue staining (LFB, bright field).
Cuprizone-fed mice showed decreased MBP+ fluorescence signal in the frontal corpus callosum (Cc), thalamus (Th) and the nucleus of the cerebellum
(Cb) in WT and CXCR3-/- mice after 5 weeks. No significant differences in the degree of demyelination were visible between WT and CXCR3-/- mice
after LFB stainings. Pictures are representative of 4 to 5 mice per group at each location and condition. B. Quantification for Mbp, Plp1 and Cnp
transcripts using TaqMan assays document equal level in WT and CXCR3-/- mice at all dissected time points of the experiment. The most rapid
drop of myelinogenic gene expression has been documented at the acute stage of demyelination after 3 weeks of cuprizone diet. Upregulation
of the level of myelinogenic transcripts were found after withdrawal of cuprizone for 4 days (5.5 weeks). Data represent mean ± SEM, n = 4 to 5
for each genotype and time point.
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fied using sections of both genotypes from correspond-
ing brain regions. In thalamic regions and the corpus
callosum, we could find significantly reduced numbers
of GFAP+ cells in CXCR3-/- compared to WT animals
(Figure 5C; WT Th: 325 ± 25 versus CXCR3-/- Th: 219 ±
33 and WT Cc: 556 ± 48 versus CXCR3-/- Cc: 384 ± 43
*P <0.05, cells/mm2).
Attenuated levels of proinflammatory transcripts in
CXCR3-deficient mice correlate with diminished
accumulation and activation of microglia and astrocytes
To correlate the observation of diminished glial activation
with changes in the local cytokine milieu, we compared
the brain levels of key inflammatory cytokines during
cuprizone treatment of CXCR3-deficient and WT mice.
Consistent with the histopathologic features, the induc-
tion of various tested cytokines and chemokines was most
striking after three weeks in WT animals. At that time
point we could detect no (IL6, Ifng, Cxcl9 and Ccl5) or
only minimal (Tnf, Ccl2, Ccl3 and Cxcl10) upregulated
transcripts in CXCR3-/- mice compared to untreatedcontrols. After 3 weeks, the CXCR3 ligands Cxcl9 and
Cxcl10 were found highly upregulated in WT (Figure 6,
Cxcl9: WT ctrl. 1.1 ± 0.2 × 10−5 versus WT 3 weeks 3.6 ±
1.3 × 10−4, Cxcl10: WT ctrl. 4.2 ± 0.3 × 10−4 versus WT
3 weeks 5.6 ± 1.8 × 10−3, copies of mRNA/Gapdh). Simul-
taneously, transcripts for the pro-inflammatory cytokines
Tnf (3 weeks, WT: 1.6 ± 0.3 × 10−4 versus CXCR3-/-: 3.9 ±
0.9 × 10−5, copies of mRNA/Gapdh), Il6 (3 weeks, WT:
1.2 ± 0.3 × 10−4 versus CXCR3-/-: 3.8 ± 0.4 × 10−6, copies
of mRNA/Gapdh) and Ifng (3 weeks, WT: 6.2 ± 2.5 × 10−5
versus CXCR3-/-: 1.4 ± 3.6 × 10−6, copies of mRNA/
Gapdh) peaked in WT but were strongly reduced in
CXCR3-/- animals.
Decreased quantities for Tnf, IL6, Ifng, Cxcl9, Cxcl10,
Ccl2, and Ccl5 transcripts were detectable throughout
all later time points in WT brains (Figure 6, 5 and
5.5 weeks), ultimately reaching the levels in CXCR3-/-
animals. In contrast to all other targets, we only found
Ccl3 with its highest level after 5 weeks in WT and
CXCR3-/- animals.
The findings of the qRT-PCR analysis outline a striking
attenuation of proinflammatory cytokines in CXCR3-
Figure 5 Astrocytes exhibit diminished morphological activation in CXCR3-/- animals. A. By using morphometric analysis of equal sections
in wild type (WT) and CXCR3-/- mice, we noticed a significant increase of the mean astrocyte perimeter in corpus callosum (Cc) and thalamus
(Th) regions after five weeks of cuprizone diet (n≥ 700 GFAP+ cells per genotype and central nervous system (CNS) region, *P <0.05, ***P <0.001).
B. Combined immunofluorescence staining for astrocytes-specific GFAP and microglia using tomato lectin demonstrates reduced cellular
extensions and less pronounced hypertrophic GFAP+ astrocytes in CXCR3-deficient brains. These findings were detectable close to zones of
microglia activation in the Cc (not shown) and Th (overview together with enlarged insets below). C. Quantification of GFAP+ cells in both regions
of interest indicates increased numbers in WT compared to CXCR3-deficient mice (*P <0.05). Data represent mean ± SEM.
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feeding.
Cuprizone-mediated demyelination is not significantly
altered in CXCR3-deficient mice
Cuprizone ingestion induces a highly reproducible and
robust demyelination of multiple brain regions in WT
mice. We applied Luxol fast blue (Figure 4 A, LFB) rou-
tine stainings and immunohistochemistry (Figure 4A,
myelin basic protein, MBP) to detect demyelination in
WT and CXCR3-/- brains at all time points examined.
By using microscopy and image analysis of serial sec-
tions at various CNS regions, no differences in the de-
gree of demyelination were documented between WT
and CXCR3-/- after five weeks of cuprizone administra-
tion (Figure 4A). At this stage of chronic demyelination in
WT and CXCR3-/- mice, robust demyelination was moni-
tored in the corpus callosum, thalamus/hypothalamus and
the cerebellum.
Furthermore, we performed qPCR of myelin basic pro-
tein (Mbp), proteolipid protein (myelin) 1 (Plp1) and
2',3'-cyclic nucleotide 3' phosphodiesterase (Cnp), which
indicates oligodendrocytic gene transcription of myelin
protein components (Figure 4B). Downregulation of
these mRNA species clearly precedes the onset of sig-
nificant demyelination after three weeks of the cuprizone
study. These changes were indistinguishable between
WT and CXCR3-/- mice (Figure 4B; Mbp, Plp1 and Cnp
level in WT 3 weeks versus CXCR3-/- 3 weeks). Afterfive weeks expression of Cnp returned to normal control
values (Figure 4B, WT 5 weeks: 4.6 ± 0.5 × 10−2 versus
WT 0 weeks: 4.5 ± 0.1 × 10−2 and CXCR3-/- 5 weeks:
4.3 ± 0.4 × 10−2 versus CXCR3-/- 0 weeks: 4.5 ± 0.1 × 10−2;
copies of mRNA/Gapdh) or were found higher in case of
Mbp transcripts (Figure 4B, WT 5 weeks: 4.6 ± 0.7 × 10−2
versus WT 0 weeks: 20.0 ± 0.2 × 10−2; copies of mRNA/
Gapdh). Again, no significant differences were detectable
between WT and CXCR3-/- animals. We could also dem-
onstrate the reappearance of Plp1 expression during late
stages of acute demyelination at five weeks, whereas levels
did not reach the corresponding control level (Figure 4B,
WT 5 weeks: 14.6 ± 0.2 × 10−2 versus WT 0 weeks: 4.8 ±
0.7 × 10−2 and CXCR3-/- 5 weeks: 4.0 ± 0.6 × 10−2 versus
CXCR3-/- 0 weeks: 12.9 ± 0.3 × 10−2; copies of mRNA/
Gapdh, mean ± SEM). Withdrawal of cuprizone diet did
not alter the levels for myelin specific transcripts detect-
able between WTand CXCR3-/- animals.
Discussion
Glial activation is a key feature of neuroinflammatory and
neurodegenerative diseases. Depending on their functional
state, glial cells can have both a beneficial and a harmful
impact on the course of neurological diseases. Under-
standing which factors control and modulate glial acti-
vation is critical to understand these diseases and to
develop novel therapeutic approaches. Here, we exam-
ined the impact of the chemokine receptor CXCR3 on
glial activation in cuprizone-induced demyelination as a
Figure 6 Substantially reduced transcripts for proinflammatory cytokines and chemokines in CXCR3-/- brains. Total RNA was isolated
from freshly prepared brain homogenates using Trizol before cDNA was synthesized using Superscript III enzyme. TaqMan gene expression assays
revealed a strongly reduction of various inflammatory transcripts after three weeks of cuprizone diet in CXCR3-deficient brain. Note the early
induction of Cxcl9, Cxcl10, Ccl5 and Ccl2 mRNA expression levels after three weeks of cuprizone diet, correlating with the high levels of Tnf, Il6 and
Ifng in WT brains. In contrast, in CXCR3-/- brains, transcript levels only slightly increased compared to control levels (0 weeks). Values were
normalized against a housekeeping gene Gapdh (*P <0.05, **P <0.005, ***P <0.001, mean ± SEM, n = 4 to 5 for each genotype and time point).
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both microglia and astrocytes without a major influx of
hematogenous immune cells like lymphocytes or mono-
cytes [56,59]. This is in contrast to most of the previous
studies examining CXCR3 in the context of neuroin-
flammatory models with a high influx of hematogenous
leukocytes into the brain tissue.
First, we observed that the clinical phenotype and the
weight loss accompanied with cuprizone intoxication
were attenuated in CXCR3-deficient mice when compared
to wild type animals. Although the clinical phenotype dur-
ing cuprizone feeding is well described [57,58], the patho-
physiological mechanisms are not yet defined. Therefore,
we can only speculate how CXCR3 deficiency leads to the
attenuated phenotypical changes. The observed changes
in glial activation and cytokine profile as discussed later
might be an indicator for similar changes in peripheral
organs like the liver, which in turn become reflected by
clinical symptoms and weight loss.
When examining the glial phenotype, we examined
whole sagittal brain sections because the dynamics ofcuprizone-induced demyelination and glial activation dif-
fer widely between the brain areas [60-62]. We character-
ized microglial activation by lectin histochemistry and
found differences in microglial activation for all examined
brain regions. The differences in areas like the cerebellum
or the thalamus were striking and highly significant. Not-
ably, the effect of CXCR3 on microglial accumulation and
glial activation was less prominent in the corpus callosum,
although cuprizone-induced myelination is most distinct
in this area. These regional differences of the effect of
CXCR3-deficiency might be explained with the different
state of demyelination in these areas. Very extensive de-
myelination as observed in the corpus callosum could
lead to a maximal microglial activation, which cannot
be attenuated by the loss of one modulating factor like
CXCR3. Still, these findings demonstrate the potent effect
of CXCR3 on glial activation in the examined model. The
differences in microglial activation were further substanti-
ated by co-localization of the microglial activation marker
CD68, which was much lower expressed in microglia from
CXCR3-deficient mice, and by flow cytometry. Here, we
Krauthausen et al. Journal of Neuroinflammation 2014, 11:109 Page 10 of 12
http://www.jneuroinflammation.com/content/11/1/109found most prominent differences in CD45 and CD11b
after three weeks of cuprizone feeding.
The modulating effects of CXCR3 were not restricted
to microglial cells. GFAP staining and analysis of GFAP+
cells revealed that GFAP+ astrocytes were less frequent
and less activated by morphological criteria in CXCR3-
deficient mice. However, we cannot discriminate if this
observation is directly induced by CXCR3 deficiency
or the consequence of reduced microglial activation.
Skripuletz et al. demonstrated in a recent study that a
lack of astrocytes during cuprizone feeding results in
less demyelination and less microglial activation and
found evidence that this effect is mediated by a lack of
astrocytic CXCL10 [63]. In regard to our study, we
cannot exclude that the changes in microglial activa-
tion we observe are at least partly caused by a reduced
synthesis of CXCL10 by CXCR3-deficient astrocytes.
However, a study examining the effect of chronic expres-
sion of cerebral CXCL10 could not detect an impact of
CXCL10 on microglial activation [64]. As astrocytes and
microglia intimately interact and both carry the CXCR3
receptor, it is likely that the lack of CXCR3 on microglia
and astrocytes has a synergistic effect on the activation of
the cell types [65].
To evaluate the impact of the reduced glial activation
on the inflammatory milieu during cuprizone treatment,
we determined the RNA levels of key inflammatory cyto-
kines and chemokines. Corresponding to the activation
time-course revealed by flow cytometry, we found a strik-
ing attenuation of all inflammatory molecules examined.
This was most prominent for prototypical proinflamma-
tory cytokines like TNFα or the chemokine CCL2. Inter-
estingly, the RNA levels of the CXCR3 ligands CXCL9 and
CXCL10 were drastically reduced and comparable to
untreated controls in CXCR3-deficient mice. This might
argue for an auto- or paracrine loop in which CXCR3-
activation increases the production of CXCR3 ligands in
glial cells.
Lastly, we characterized the impact of CXCR3 on the
course of de- and remyelination in different areas of the
brain. Despite the striking changes in the glial activation
and cytokine expression, we could not detect a significant
change in the course of de- and remyelination. Neither
histological evaluation nor the course of the molecular
markers Mbp, Plp1 or Cnp revealed differences of de- and
remyelination between CXCR3-competent and CXCR3-
deficient mice. Although there is some evidence that oli-
godendrocytes express a functional CXCR3 receptor
[66,67], the lack of differences in demyelination argues
strongly against a direct modulatory effect of CXCR3 on
the extent of oligodendrocyte damage in this model.
During remyelination after cuprizone-induced demyelin-
ation, oligodendrocyte precursor cells become recruited,
proliferate and have to undergo maturation [68,69].Although we did not analyze the oligodendrocyte popu-
lation in extent, we could not observe differences in the
increase of myelin-related RNA levels after cessation of
cuprizone feeding, nor in the amount of remyelination.
This argues, like discussed for demyelination, against a
function of CXCR3 in remyelination after cuprizone
demyelination.
Conclusions
In conclusion, our findings argue for a major role of
CXCR3 in the endogenous activation of glial cells in-
duced by cuprizone-mediated demyelination. This pro-
vides further evidence for an important role of this
chemokine receptor in modulating the function of
microglia and astrocytes.
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